tax loss selling, page-5

as FP said, never say never, but it is my understanding that US ODS has little to do with CVac itself but more to do with the statistics surrounding new patients per year and or R&D costs vs. revenue.

From what I have read, CVac would qualify given the 'rarity' of ovarian cancer. I would also suggest that given DNDN's success and the FDA's acceptance of CVac to this point will bode well for CVac obtaining US ODS.

I dont expect that this will have much impact on the SP or attract any big pharma's, I tend to agree with raymona in that positive ph11b trials will be a more likely vehicle for this kind of action.

never say never.